These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38828426)

  • 21. An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.
    Becker KA; Jones JJ
    Adv Ther; 2018 Jan; 35(1):5-11. PubMed ID: 29285707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
    Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR
    Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
    Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR
    J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
    Yamada M; Osamura M; Ogura H; Onoue T; Wakamatsu A; Numachi Y; Caltabiano S; Mahar KM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):978-984. PubMed ID: 32250021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.
    Kanai H; Nangaku M; Nagai R; Okuda N; Kurata K; Nagakubo T; Endo Y; Cobitz A
    Ther Apher Dial; 2021 Dec; 25(6):979-987. PubMed ID: 33964183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
    Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
    Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
    Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
    Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A
    Nephrol Dial Transplant; 2022 Apr; 37(5):960-972. PubMed ID: 33744933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daprodustat for Post-Transplant Anemia in Renal Transplant Recipients.
    Machida Y; Iwai T; Kabei K; Naganuma T; Uchida J
    Transplant Proc; 2024 Apr; 56(3):534-539. PubMed ID: 38355374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
    Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
    Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemistry, Analysis, and Biological Aspects of Daprodustat, A New Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor: A Comprehensive Review.
    Patil R; Sharma S
    Mini Rev Med Chem; 2024; 24(20):1847-1855. PubMed ID: 38685804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia.
    Shimada Y; Izumi Y; Yasuoka Y; Oshima T; Nagaba Y; Nanami M; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.
    Holdstock L; Cizman B; Meadowcroft AM; Biswas N; Johnson BM; Jones D; Kim SG; Zeig S; Lepore JJ; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):129-138. PubMed ID: 30746140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.